CLINUVEL

COMPANY ANNOUNCEMENT

Board changes after AGM

Melbourne, Australia, 29 September 2023	ASX:	CUV
	Börse Frankfurt:	UR9
	ADR Level 1:	CLVLY

CLINUVEL PHARMACEUTICALS LTD confirms changes to the composition of its Board of Directors effective following its Annual General Meeting (**AGM**) on 31 October 2023.

The Company's Notice of Meeting for the AGM has been lodged with the ASX today and is available on the Company's website at www.clinuvel.com.

Non-Executive Director Sir Andrew Likierman, who has been a member of the Board of Directors since April 2022, will resign from his position at the conclusion of the AGM to focus on his various academic and consultancy activities.

Mr Willem Blijdorp has announced he will step down as Chairperson of the Board of Directors with effect from of 1 January 2024, pending his re-election as a Non-Executive Director at the Company's AGM. The Board has commenced a review process, after which a new Chairperson will be announced.

"On behalf of my fellow Directors, I thank Sir Andrew for his service and wish him well with his future endeavours," Mr Blijdorp said. "I remain committed to continuing my role at CLINUVEL, supporting the Board and management team as the Company is expanding. During this important and exciting phase, I intend to play an active role in assisting the Company reach new markets in 2024 and beyond."

– END –

CLINUVEL's AGM will be held on Tuesday, 31 October 2023 at 10.00am (AEDT) at The Events Centre at Collins Square, Tower 2, Level 5, 727 Collins Street, Melbourne, VIC 3008, Australia. Shareholders may also view the meeting via live webcast by registering at https://loghic.eventsair.com/cuv2023agm/cuvagm/Site/Register.

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL's lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to https://www.clinuvel.com. Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD

Head of Investor Relations
Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries
https://www.clinuvel.com/investors/contact-us

Forward-Looking Statements
This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg), PRÉNUMBRA® or NEURACTHEL®; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, Israel, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, PRÉNUMBRA® or NEURACTHEL® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2023 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

Contact

+61 3 9660 4900
+61 3 9660 4909

www.clinuvel.com

Level 11, 535 Bourke St
Melbourne, 3000 Vic, Australia